Ken Griffin Morpho Sys Ag Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.6 - $18.18 $813,594 - $1.72 Million	-94,604 Reduced 96.34%	3,594 $65,000
Q4 2023 Feb 14, 2024	SELL	$4.55 - $9.9 $159,623 - $347,311	-35,082 Reduced 26.32%	98,198 $972,000
Q3 2023 Nov 14, 2023	BUY	$6.72 - $8.6 $664,251 - $850,084	98,847 Added 287.07%	133,280 $895,000
Q2 2023 Aug 14, 2023	BUY	$3.95 - $7.74 $136,010 - $266,511	34,433 New	34,433 $257,000
Q3 2022 Nov 14, 2022	BUY	$4.14 - $22.13 $83,002 - $443,684	20,049 New	20,049 $101,000
Q1 2022 May 16, 2022	SELL	$5.87 - $9.73 $298,237 - $494,352	-50,807 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$9.08 - $12.45 $461,327 - $632,547	50,807 New	50,807 $478,000
Q1 2021 May 17, 2021	SELL	$21.56 - $30.66 $730,517 - $1.04 Million	-33,883 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$24.81 - $30.33 $1.78 Million - $2.18 Million	-71,808 Reduced 67.94%	33,883 $960,000
Q3 2020 Nov 16, 2020	SELL	$30.28 - $35.72 $344,192 - $406,029	-11,367 Reduced 9.71%	105,691 $3.32 Million
Q2 2020 Aug 14, 2020	BUY	$24.08 - $33.35 $2.09 Million - $2.89 Million	86,653 Added 285.0%	117,058 $3.71 Million
Q1 2020 May 15, 2020	BUY	$18.86 - $37.36 $137,828 - $273,026	7,308 Added 31.64%	30,405 $747,000
Q4 2019 Feb 14, 2020	BUY	$26.07 - $36.32 $139,787 - $194,747	5,362 Added 30.23%	23,097 $824,000
Q3 2019 Nov 14, 2019	SELL	$24.18 - $31.58 $11,703 - $15,284	-484 Reduced 2.66%	17,735 $487,000
Q2 2019 Aug 14, 2019	BUY	$23.24 - $26.76 $63,398 - $73,001	2,728 Added 17.61%	18,219 $440,000
Q1 2019 May 15, 2019	SELL	$22.55 - $29.84 $108,420 - $143,470	-4,808 Reduced 23.69%	15,491 $0
Q4 2018 Feb 14, 2019	SELL	$21.96 - $31.02 $1.32 Million - $1.87 Million	-60,206 Reduced 74.79%	20,299 $513,000
Q2 2018 Aug 10, 2018	BUY	$25.15 - $30.6 $2.02 Million - $2.46 Million	80,505 New	80,505 $0

Others Institutions Holding MOR

# of Institutions

Shares Held

1.8M

Call Options Held

Put Options Held

14.7K

View Full List

About MorphoSys AG

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

More about MOR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account